CBD Extract Suppressed Immune Cell Activation More Effectively Than Standard Immunosuppressants in Lab Tests

The CBD-rich extract CAN296 reduced T cell activation markers (CD69) to 2-11% in CD4+ cells and 5-17% in CD8+ cells. It nearly eliminated TNF-alpha and IFN-gamma secretion in CD8+ cells at all tested doses. These effects were more potent and consistent than either dexamethasone or tacrolimus.

CD4+ and CD8+ T cells isolated from healthy donors were treated with a CBD-rich cannabis extract (CAN296) at three doses and compared to dexamethasone and tacrolimus. Researchers measured T cell activation, cytokine secretion (TNF-alpha, IFN-gamma), and cytotoxic molecule expression (Granzyme B, Perforin, Fas-L).

Oral lichen planus and graft-versus-host disease are T cell-driven conditions with limited treatment options. The finding that a CBD-rich extract outperformed two standard immunosuppressants at controlling T cell activity suggests a potential new therapeutic approach for these conditions.

Standard immunosuppressants like dexamethasone and tacrolimus come with significant side effects. If CBD-rich extracts can match or exceed their efficacy at controlling immune responses, this could open a pathway to treatments with potentially fewer adverse effects.

In vitro study using cells from healthy donors only, cannot predict clinical efficacy or safety, specific CBD-rich extract (CAN296) may not represent all CBD products, dose ranges may not correspond to achievable tissue concentrations in patients